Cell Transplant in Spinal Cord Injury Patients

Cairo University80 enrolled

Overview

This study is designed to assess the safety of autologous bone marrow derived cell transplant in chronic spinal cord injury patients. The hypothesis is that the availability of bone marrow derived mesenchymal stem cells at the sites of injury promote neuronal regeneration.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Chronic Spinal Cord Injury

Interventions

Autologous bone marrow transplantPROCEDURE

Physical therapyPROCEDURE

Eligibility

Sex: ALLMin age: 10 YearsMax age: 36 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Traumatic spinal cord injury * No concomitant systemic disease * No progress on physiotherapy for at least 6 months * Duration of injury from 10 months to 3 years Exclusion Criteria: * Non-traumatic spinal cord injury whether transverse myelitis or demyelination * Concomitant systemic disease * Progress can be observed on physiotherapy * Acute injury or duration of injury less than 10 months

Locations (1)

Cairo University School of Medicine

Cairo, Egypt

Outcomes

Primary Outcomes

Safety of autologous BM transplant measured by absence of neuronal changes, infections or increased intracranial tension, and monitoring for any abnormal growth or tumor formation by MRI.

Time frame: 18 months

Secondary Outcomes

Efficacy of BM cell transplant in improving neurological functions in patients with chronic SCI. Improvement in motor, sensory and sphincteric functions, and quality of life using ASIA scores and MRI.

Time frame: 18 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.